Zydus Lifesciences Stock Upgraded: An Analysis
Key Points
- Systematix upgraded Zydus to ‘Buy’ due to new drug.
- Zycubo, a Menkes disease treatment, got FDA approval.
- Menkes disease affects about 56 newborns annually in the US.
- Early Zycubo treatment extends survival by over 160 months.
- Zydus will receive royalties and milestone payments for Zycubo.
- Revised target price set at ₹1,038, with potential profitability by FY28.
A brokerage firm, Systematix, has recently changed its opinion on Zydus Lifesciences, raising its stock rating to ‘Buy.’ This upgrade is largely based on exciting new developments within the company. Zydus is now seen as a more promising investment than before.
The main reason for this change is a new medicine called Zycubo. This drug treats a very rare disease called Menkes disease. It’s been given the green light by the U.S. Food and Drug Administration (FDA), which means doctors can now use it to help patients.
Menkes disease is tough because it’s rare. About 56 babies are diagnosed with it each year in America. Without treatment, many of these children don’t live very long – typically less than 18 months. However, Zycubo offers a real chance for a longer life.
Scientists have found that if kids start taking Zycubo soon after they’re born – within 10 days – they can live much longer. In some cases, they can live for almost 177 months, compared to about 62 months if treatment starts later. This is a huge step forward for families affected by this disease.
The approval of Zycubo makes Sentynl Therapeutics, the company selling it, look much stronger. They now have more patients who could use the drug. Experts estimate Zycubo could make around $50 million in sales each year if everyone who should be treated uses it.
Zydus will share some of the profits with Sentynl through royalties and special payments. They’ve also changed how they think about Zydus’s business in the United States, which includes a deal to sell a similar medicine called Lucentis. This has boosted Zydus’s potential earnings.
Because of all these positive changes, Systematix has raised its price target for Zydus stock to ₹1,038. This is based on what the company is expected to earn in the future. They believe Zydus could start making a profit by 2028.
Zydus Lifesciences itself had a good quarter. Their sales went up 17% compared to last year, and their profits also increased significantly, along with a better profit margin.
“This milestone marks a transformative moment for the Zydus Group and for families affected by Menkes disease,” Sharvil P. Patel, managing director, Zydus Lifesciences, had said in a statement earlier. “For the first time, patients have access to an approved therapy, offering hope where no options existed.”
Investing wisely means carefully considering new developments and potential opportunities.
“`
